Health Care & Life Sciences » Biotechnology | Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
1,766.90
2,672.10
1,308.50
5,265.00
35,408.40
31,114.30
Other Current Assets
94.60
75.30
107.00
61.70
176.70
230.80
Total Current Assets
1,861.50
2,747.40
1,415.50
5,326.70
35,585.00
31,345.10
Total Assets
1,861.50
2,747.40
1,415.50
5,326.70
35,585.00
31,345.10
Accounts Payable
225.30
-
-
-
1,071.30
Other Current Liabilities
3,182.20
2,037.40
654.30
539.10
988.60
Total Current Liabilities
3,407.40
2,037.40
654.30
539.10
2,059.90
Total Liabilities
3,407.40
2,037.40
654.30
539.10
2,059.90
Common Equity (Total)
1,545.90
710.00
761.20
4,787.50
33,525.20
Total Shareholders' Equity
1,545.90
710.00
761.20
4,787.50
33,525.20
Total Equity
1,545.90
710.00
761.20
4,787.50
33,525.20
Liabilities & Shareholders' Equity
1,861.50
2,747.40
1,415.50
5,326.70
35,585.00

About Fennec Pharmaceuticals

View Profile
Address
Research Triangle Park
Durham North Carolina 27709
United States
Employees -
Website http://www.fennecpharma.com
Updated 07/08/2019
Fennec Pharmaceuticals, Inc. is a small stage biotechnology company, which engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.